Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance
PAT +49.18% YoY · revenue +32.54% · margins expanding
₹1,794.16 Cr
+32.54% YoY
₹388.14 Cr
+49.18% YoY
21.19%
+2.8pp YoY
₹31.07
Consolidated PAT for Q2 FY27 came in at ₹388 Cr, up 49% YoY (₹260 Cr) and 16% QoQ (₹334 Cr), on revenue from operations of ₹1,794 Cr, up 33% YoY and 10% QoQ. Net profit margin expanded to 21.6% from 18.4% a year ago and 19.7% last quarter. Standalone PAT was ₹380 Cr, up 52% YoY — standalone and consolidated tell the same growth story with no material divergence. Neither this quarter nor the year-ago quarter carries an exceptional item, so the YoY growth is clean rather than base-effect driven.
Q2 FY-2027 vs prior quarters
Segment-wise, US Generics led with revenue up 41% YoY to ₹484 Cr, Africa Institution (tender-driven) revenue jumped to ₹116 Cr from ₹32 Cr (+259% YoY), and India branded generics grew a steadier 16% YoY to ₹504 Cr — ahead of IPM industry growth of 13% per IQVIA MAT September 2026 data, against Ajanta's own 17% India branded growth. Gross margin held at 78.5%, within management's guided ~78%±1% band, while adjusted EBITDA margin (excluding forex) rose to 30% from 24.2% a year ago — above the ~27%±1% full-year EBITDA guidance given on the Q3 FY26 call. The expansion is broad-based across segments rather than a single cost-line effect.
The stock went into the print at ₹3,527.1, down 0.9% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Management guided for overall mid-teens revenue growth for FY26, with Asia expected at mid-single to high-single digits and Africa at low-double digits. For FY27, US generics are projected for double-digit growth, albeit not at the current robust pace. Gross margins are expected to remain around 78% +/- 1% and EBITDA m
— This quarter: beat
On the January 2026 concall, management had guided US generics to grow in double digits for FY27 but "not at the current robust pace" — this quarter's 41% YoY US print shows that expected deceleration has not materialised yet. No Q2-specific published Street consensus was found; full-year FY27 analyst consensus pegs revenue growth at roughly 15% YoY (₹6,270 Cr), a pace H1 FY27's 29% YoY growth is already running well ahead of. The quarter also saw routine promoter-level pledge/release filings (a 30,000-share pledge on Oct 21, a 2.10% stake pledge by CTL Trusteeship on Oct 1, an NCD-linked pledge on Oct 6, and a 98,185-share release on Sep 28) — financing-related disclosures unconnected to the operating numbers.
W1
Africa Institution tender revenue (₹116 Cr this quarter, ₹187 Cr for H1) — whether it normalises or stays elevated next quarter
W2
US Generics growth pace (41% YoY this quarter) — management guided FY27 deceleration to double digits; watch if that shows up in Q3
W3
H1 FY27 adjusted EBITDA margin of 29.1% (₹997 Cr/₹3,420 Cr) vs full-year guidance of ~27%±1% — whether H2 margins hold near this beat
Clean statement, both totals tie exactly (totalIncome = revenue+other income; PAT = PBT-tax). No exceptional-items line; forex gains/losses sit inside other income/other expense (company separately reports EBITDA ex-forex). Consolidated has no minority interest.
Q2 FY27: Can Ajanta Hold Momentum as Seasons Shift?
After Q1's 25% revenue surge and 31% PAT jump, the Street expects high-teens growth to persist. Watch whether margins defend and if US generic headwinds flex.
What to Expect
~₹1,600–₹1,700 Cr
On-plan for high-teens growth trajectory; Q1 was ₹1,626 Cr (+25% YoY)
~₹320–₹360 Cr
Implies 20–21% net margin; Q1 was ₹334 Cr (+31% YoY); watch for seasonal margin deflation
~78% ±100 bps
Management guided ~78% for FY27; Q1 achieved 80% (strong). Seasonal pressure possible.
~27% ±100 bps
Q1: 28% (within guidance). Watch for opex leverage and mix shift.
A strong Q2 means revenue reaching ₹1,650+ Cr (staying above ₹1,600 threshold), PAT crossing ₹350 Cr, and both gross and EBITDA margins holding within guidance bands. A weaker-than-expected Q2 would show revenue plateauing vs Q1 or sub-₹1,600 Cr, net margin collapsing below 19%, or EBITDA margin slipping below 26%—signals of mix headwinds, US generic pressure, or cost inflation.
Tracking the Full-Year Plan
Management has guided high-teens revenue growth for FY2027—analyst consensus pegs FY27 at ₹6,270 Cr (+14.9% YoY). Q1's 25% growth is ahead of the full-year plan, but Q2 typically sees seasonal headwinds in pharma (monsoon, festival demand patterns). On-track means Q2 sustains 15–20% YoY growth. If sequential revenue softens sharply (say, below ₹1,550 Cr), it would signal either gross-margin compression or volume deceleration—red flags for full-year guidance.
What the Street Says
Since Last Quarter: Filings Scan
Oct 21, 2026
30,000 shares pledged (Oct 16) for 'top-up call' on existing loan. Routine refinancing.
Promoter Pledge: Aayush Agrawal
Oct 15, 2026
Oct 30 agenda: approve Q2 FY27 results. Standard governance.
Board Meeting Announced
Oct 6, 2026
Aayush Agrawal pledged 4.6L shares to back Non-Convertible Debenture (NCD) issuance. Capital raise.
Promoter NCD Pledge
Oct 1, 2026
2.10% of capital (26.21L shares) pledged as security for debt. Standard practice for leverage.
CTL Trusteeship Pledge
Sep 30, 2026
Filed GRI-referenced ESG disclosure. Voluntary, no material impact.
FY26 Sustainability Report
Sep 25, 2026
Closure per SEBI Insider Trading Regulations for Q2 result announcement. Routine.
Trading Window Closed
Pledges: Promoter leverage is rising—Aayush Agrawal and CTL Trusteeship have created multiple pledges since August (NCDs, refinance calls). This reflects debt-funded capex (likely for the liquid-formulations plant expansion). Not a red flag yet, but watch pledge-to-holding ratio if it creeps above 30–35% of promoter stake. ESG filing: Routine GRI disclosure, no operational surprise. Investor outreach: Management attended Jefferies and PL Capital conferences in August–September—confidence-building before result.
What to Watch on Oct 30
1 · Revenue & Volume Growth
Did Q2 sustain ₹1,600+ Cr? Look for YoY growth rate (targeting 15–20% for on-plan) and segment breakdown (India domestic vs. US generics). Sequential dip is normal but magnitude matters.
2 · Margin Defense
Gross margin at ~78% and EBITDA at ~27% = on-track. Falls below 26.5% EBITDA or 77% gross? Flag cost/mix pressure. Q1's 28% EBITDA was strong—seasonal softening to 26–27% is expected.
3 · FY27 Guidance Reaffirm
Management to comment on full-year high-teens growth, margin bands, and any US generic outlook shifts. Quiet = confidence. Guidance cut = sector headwind.
4 · Capital & Dividend
FY26 saw ₹32/share interim dividend in Q1. Watch for Q2 distribution and any capex spend update on the liquid-plant project (funded via NCD pledges).
Ajanta enters Q2 with significant momentum—Q1's 25% revenue and 31% profit growth has set a high bar, and the 86.7% Buy consensus reflects confidence in FY27's high-teens growth plan. The Street's 2.2% upside from here is modest, signaling the stock is fairly valued on delivery risk.
The real test: can Q2 sustain ₹1,600+ Cr revenue while defending margins as seasonal headwinds emerge? Gross margin holds at ~78%, EBITDA at ~27%, and management reaffirms full-year guidance—those are the three pillars that keep the upside intact. A beat on volume or surprise capex efficiency could ignite a re-rating.